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Mellitus Type 2 (DM II), a chronic condition that many people suffer from across the globe. Cinnamon may
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this systematic review. Studies that evaluated the effect of cinnamon on HBA1C, lipids, and fasting plasma
glucose were included, only to extract the data in relation HBA1C.
Results: The initial search resulted in 30 articles. Of those, only 4 were randomized control trials that analyzed
the efficacy of cinnamon supplementation on HBA1C levels were identified. Thus, 4 articles were included in
this systematic review.
Conclusion: This systematic review illustrates that the efficacy of cinnamon supplementation on HBA1C is
statistically insignificant, and the data thus far does not strongly support its use. Further research should
analyze different variables, such as age, gender, race, insulin sensitivity, diet and diabetic regimen. Future
research should also analyze any synergistic relationship that cinnamon supplementation may have with
different diabetes medications. At this time, cinnamon supplementation for the purpose of controlling
diabetes is not recommended. However, future studies may reveal that medicinal cinnamon is beneficial. As it
is inexpensive, readily available, and potentially free of side effects, further investigation is warranted.
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Abstract   
 
 
Background:   For years cinnamon has been used in treating a variety of ailments, in addition to its 
use as a spice. Recently, researchers have been looking at supplementation of cinnamon and its affect 
on Diabetes Mellitus Type 2 (DM II), a chronic condition that many people suffer from across the 
globe. Cinnamon may help in reducing the HBA1C because of its insulin potentiating activity. The 
purpose of this systematic review was to investigate the efficacy of cinnamon on lowering HBA1C 
levels.  
Methods:  An extensive search using CINAHL, MEDLINE, Evidence Based Medicine Reviews 
Multifile and Web of Science was performed. Included in the search were non-insulin and insulin 
dependent DM II participants of either gender, any age, and from any country. Only randomized 
control trials were included in this systematic review. Studies that evaluated the effect of cinnamon on 
HBA1C, lipids, and fasting plasma glucose were included, only to extract the data in relation HBA1C.  
Results:  The initial search resulted in 30 articles. Of those, only 4 were randomized control trials that 
analyzed the efficacy of cinnamon supplementation on HBA1C levels were identified. Thus, 4 articles 
were included in this systematic review.  
Conclusion:  This systematic review illustrates that the efficacy of cinnamon supplementation on 
HBA1C is statistically insignificant, and the data thus far does not strongly support its use. Further 
research should analyze different variables, such as age, gender, race, insulin sensitivity, diet and 
diabetic regimen. Future research should also analyze any synergistic relationship that cinnamon 
supplementation may have with different diabetes medications. At this time, cinnamon 
supplementation for the purpose of controlling diabetes is not recommended. However, future studies 
may reveal that medicinal cinnamon is beneficial. As it is inexpensive, readily available, and 
potentially free of side effects, further investigation is warranted.  
Keywords:  HBA1C, hemoglobin A1C, glycated hemoglobin A, cinnamon, cinnamomum, 
cinnamomum cassia, cinnamomum zeylanicum, diabetes mellitus type 2   
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Does Cinnamon Supplementation help lower HBA1C in Patients with Diabetes 
Mellitus Type II? 
 
BACKGROUND 
DM II is a disease that affects millions of people across the globe. It causes a number of 
comorbid conditions and complications; and also costs billions of dollars annually. With the increasing 
cost of pharmaceuticals and the risk of adverse reactions that come along with them, it is worthwhile to 
devote research to analyzing safe, naturally occurring, and relatively inexpensive alternative treatments 
for DM II. Herbal remedies have been passed down for generations to treat a variety of illnesses. One 
such remedy is the use of cinnamon. Cinnamon is a spice that is mainly cultivated in Asia, South 
America, and the Caribbean.1 There are two common types of cinnamon, cinnamomum cassia or 
aromaticum2(C. cassia or C. aromaticum) and cinnamomum verum or zeylanicum3,4(C. verum or C. 
Zeylanicum). Cinnamon has been used since ancient times to treat many ailments. Some common 
ailments that are alleviated by the use of cinnamon are nausea, diarrhea, fungus, and pain.1 Cinnamon 
is made up of many chemical components that are responsible for alleviating these symptoms. Some of 
these contributory constituents are eugenol, cinnamaldehyde, coumarins, and polyphenols.5 It is 
postulated by researchers that cinnamon has insulin-potentiating effects, thus allowing more insulin to 
be readily available for cellular glucose uptake.6   There have been many studies that have conducted 
in vivo and in vitro trials to analyze the relationship that cinnamon has with insulin. Such studies 
demonstrate that certain components of cinnamon increase insulin receptor kinase activity and 
glycogen synthesis, in addition to inducing phosphorylation of insulin receptors.7,8 This means that 
components in cinnamon stimulate insulin receptors, inhibit the enzyme that inactivates insulin 
receptors, and help the liver utilize glycogen, thus allowing for glucose to be taken up by the cells. 
Further research and investigation is needed to evaluate the chemical components of cinnamon and 
their effect on insulin activity. Thus far, there have been conflicting data on whether cinnamon 
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supplementation could be a worthwhile addition to the DM II treatment regimen. The purpose of this 
systematic review is to focus on cinnamon supplementation and its effect on hemoglobin A1C 
(HBA1C) in DM II. The hope is that cinnamon can be added to the diabetes treatment plan as a 
relatively safe and inexpensive supplement that may benefit patients who have difficulty gaining tight 
control of their HBA1C. It is also hopeful that cinnamon could reduce patient financial burden, the 
likelihood of complications of diabetes like nephropathy, neuropathy, and retinopathy, decrease the 
risk of potential unknown long term affects that new diabetes medications may have, and also reduce 
the likelihood of adverse effects associated with poly-pharmacy.  
METHODS 
A detailed search using MEDLINE, CINHAL, Web of Science, and Evidence Based Medicine 
Reviews Multi-file was conducted without restricting the date that the studies were done. The 
following keywords were used in the search: “HBA1C”, “Hemoglobin A1C”, “Glycated hemoglobin 
A”, in combination with:  “Cinnamon”, “Cinnamomum”, “Cinnamomum Cassia”, “Cinnamomum 
aromaticum”, “Cinnamomum zeylanicum”, “Cinnamomum verum”, in combination with: “Diabetes 
Mellitus Type 2” and “DM II”. Results were limited to clinical trials in humans. A search of references 
was also conducted within the articles that were selected for review. Articles were evaluated for 
validity using the Jadad score. The method of randomization and blinding were evaluated for each of 
the articles included in this systematic review. Articles were also evaluated for similarity of 
participants amongst groups, equal treatment between groups, and that each of the participants was 
accounted for. 
To be included in this systematic review the studies had to have been randomized control trials 
that evaluated the relationship of cinnamon and its efficacy in lowering HBA1C in DM II. These 
studies did not have to be double-blind in design. The type of cinnamon supplemented was not 
restricted; the search included c. cassia, c. aromaticum, c. verum, and c. zeylanicum. The formulation 
(i.e. pill, extract, or powder) and dosage of the cinnamon supplement was not restricted. Non-insulin 
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dependent and insulin dependent DM II patients of either gender and of any age were included. The 
search was not restricted by the country in which it was conducted. Due to the minimal research 
available in databases regarding this topic, studies were not restricted to just those analyzing the 
relationship of cinnamon supplementation and HBA1C alone. Therefore, studies that analyzed HBA1C 
and additional factors, such as lipids and fasting plasma glucose were included. The data that analyzed 
the relationship of HBA1C and cinnamon supplementation was then extracted from these studies. 
Minimal exclusion criteria were incorporated in this search. However, type I Diabetes Mellitus patients 
were excluded from this search.  
RESULTS 
The initial search resulted in 30 articles, from 4 databases: CINAHL, MEDLINE, Evidence 
Based Medicine Reviews Multi-file, and Web of Science. Of those, 4 were randomized control trials 
that evaluated the relationship of cinnamon supplementation to its affect on HBA1C levels were 
selected. The remaining 26 did not meet the population, exclusion, and/or inclusion criteria that were 
set prior to conducting the literature search. See Table 1 for a summary of the included studies. 
 The first study that was reviewed was conducted by Crawford,9 published in 2009. The study’s 
objective was to determine the efficacy of cinnamon supplementation on lowering HBA1C levels in 
Type II Diabetics. He recruited participants for the study via phone calls from volunteers to patients 
from the 96th Medical Group, Eglin Air Force Base in Florida. Inclusion criteria for the participants 
were as follows, HBA1C of ≥ 7 within 6 months prior to the study, greater than 18 years of age, and of 
either gender. Exclusion criteria were as follows, participants that were pregnant, <18 years of age, and 
those that had a cinnamon allergy. Other variables that were considered were race, BMI, insulin use, 
addition or removal of diabetic medication during the trial, and cinnamon intake prior to the study. 
Neither the participants nor the investigators were blinded, but the lab personnel were blinded to which 
samples belonged to either the control or treatment group. 109 participants were included in the study 
initially, 55 were assigned to the treatment group and 54 to the control group. Male and female 
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participants were noted for the original 109, but gender was not specified in each of the groups for the 
actual number who completed the trial. Out of the 109 participants there were 32 males and 23 females 
in the treatment group, and 32 males and 22 females in the control group. There were 9 participants 
disqualified from the treatment group for reasons of rash (1), relocation (1), inconvenience (2), and 
unknown (5). Therefore, a total of 46 participants in the treatment group completed the study. Of the 
54 participants in the control group, 11 were disqualified because they forgot about enrollment in the 
trial (1), inconvenience (2), and unknown (8). This resulted in 43 participants in the control group 
completing the study. Average age in the treatment group was 60.5 +/- 10.7 and 59.9 +/- 9.2.9 
The participants in treatment and control group were measured for their baseline HBA1C at the 
beginning and also at 90 days. Follow-up HBA1C was obtained from days 90 to 95.  The treatment 
group was treated with 2 tablets of 500mg C. cassia for a 3 month period, in addition to continuing 
their normal diabetic therapy. The control group participants were not given any form of placebo, but 
were to continue their normal diabetic therapy. Compliance in the groups was monitored via phone 
interview towards the end of the trial period. Crawford carried out an intention to treat analysis of the 
initial 109 participants. The baseline HBA1C in the treatment group was 8.47 +/- 1.8 and post 
treatment HBA1C was 7.64 +/-1.7. Cinnamon lowered HBA1C 0.83% (95% CI, 0.45-1.20). This 
produced a p value of <.001. The baseline HBA1C in the control group was 8.28 +/- 1.3 and the post 
treatment HBA1C was 7.9 +/- 1.5.  The usual care lowered HBA1C by 0.37% (95% CI, 0.15-0.59), 
producing a P value of 0.16. Values between baseline and final HBA1C were compared with an 
unpaired 2 sample t-test. This study found that cinnamon supplementation may be worthwhile to 
initiate in patients with poor control of their DM II.9 
The second study reviewed led by Mang et al10 was published in 2006. In this study, the 
objectives were to analyze the effect of cinnamon extract on plasma glucose, HBA1C, and serum lipids 
in patients with DM II. For the purpose of this review, HBA1C was the only result that was analyzed. 
There were 79 patients from Hannover, Germany selected for the study. Included in the study were 
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patients with DM II on oral anti-diabetic medication or those who had diet controlled diabetes. 
Excluded were those on insulin therapy. It is assumed that there were no specific inclusion or 
exclusion criteria with regard to any demographic data, since no such criteria were mentioned in the 
methods section. Variables that were taken into account in addition to participant demographics, were 
time since diagnosis, height, weight, BMI, and waist circumference. The study stated that a double 
blind method of randomization was used. Of the 79 patients selected for the study, 2 were withdrawn 
from the study because of weight changes of ≥5% during the trial period, 7 withdrew consent, 4 had 
serious disease, and 1 for irregular intake of the study preparation. Therefore, 65 participants actually 
were included in the trial. 33 patients were assigned to the treatment group and 32 to the control group. 
In the treatment group there were 21 men and 12 women, and in the control group there were 23 men 
and 9 women. Average age of the treatment group was 62.8 +/- 8.37 and 63.7 +/- 7.17 in the control 
group.10 
The treatment group was assigned to take one 112mg capsule of cinnamon extract (equal to 1 
gram of cinnamon) 3 times daily. The control group was given an identical tablet that contained 
crystalline cellulose and they were to take it 3 times daily. The trial period lasted 4 months. Baseline 
and end of trial HBA1C were obtained in each of the groups. Compliance was monitored by capsule 
count and missed pills were logged into a diary. The baseline HBA1C in the treatment group was 6.86 
+/- 1.00 and the post trial result was 6.83 +/- 0.83. Thus resulting in a difference of 0.05 +/- 0.43. The 
baseline HBA1C in the control group was 6.71 +/- 0.73 and the post trial result was 6.68 +/-0.70. Thus 
resulting in a difference of 0.03 +/-0.79. No significant results were observed within or between the 
groups with regard to HBA1C levels. 10 
The third study that was reviewed was conducted by Blevins et al11 and was published in 
September 2007. This study was conducted at the University of Oklahoma and analyzed cinnamon 
supplementation and its affect on fasting plasma glucose, cholesterol, HBA1C, and insulin levels. BMI 
was also taken into account for each of the groups. For the purpose of this review, only the HBA1C 
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results will be analyzed. Participants were contacted via a campus listserv and also through the local 
paper. Inclusion criteria were as follows, people of any age with DM II. Excluded were those that had 
insulin dependent DM II, those already using cinnamon supplementation, if they had an HBA1C of 
<6%, or if they had an acute illness.  Also, participants were not able to initiate or withdraw from 
certain medications during the trial period.11 
There were 77 participants selected for the trial. This study stated that participants were 
assigned to groups in a randomized fashion, but the method of randomization was not explained. Out 
of the 77 participants selected, 17 were disqualified. 14 people had HBA1C level <6% and 3 
participants had acute illnesses. Out of the remaining 60 participants, only 43 completed the study. 
Participants that did not complete the trial were those that had a change in their diabetic or cholesterol 
regimen (5), began to take cinnamon supplementation not authorized by the study (1), motor vehicle 
accident (1), inconvenience (1), dissatisfaction with the trial (1), and relocation (1). There were 57 
participants included in the intention to treat analysis. This study did not specify the number of men 
and women in each of the groups, nor did it give the average age of the participants. The treatment 
group was given 500mg C. cassia capsules and the control group was given 500mg placebo wheat 
flour capsules, to be taken twice daily for 3 months. HBA1C were measured at baseline and at 3 
months, which was the end of the trial period. Pretrial A1C was 7.2 +/- 0.3 and 7.1 +/- 0.2, respectively 
in the treatment and control group (p=0.60). The change in HBA1C in the treatment group was 0.2 +/- 
0.1 and 0.1 +/- 0.2 in the control group (p=0.63). No significant change in HBA1C between the 
treatment and the control group was observed.11 
 The last of the studies in this systematic review was conducted by Suppapitiporn et al12, 
published in 2006. The participants were from the King Chulalongkorn Memorial Hospital in 
Thailand. The study focused on the effect C. cassia powder has on plasma glucose, lipid profile and 
HBA1C. Other variables that were taken into account were body weight, BMI, and number of years 
since diagnosis. BUN, creatinine, SGOT, SGPT, and blood pressure were monitored during the trial. 
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For the purpose of this review, only HBA1C data was extracted for analysis. Inclusion criteria were as 
follows, participants had to take their regular diabetes medications at least for 3 months prior to 
enrollment in the study, needed to be between the age of 30-70, have a HBA1C >7% within one month 
prior to enrolling in the study, with a fasting plasma glucose of 120-180mg/dl, and those that were 
females of childbearing age were to have proper form of contraception. Excluded were those with DM 
I; or DM II patients treated with insulin within 3 months prior to the study, diabetes linked to chronic 
pancreatitis, hemochromatosis, genetic defect in insulin action, disorders of b-cell function, renal 
disease, liver disease, or those with poorly controlled DM II due to concurrent illness, infection, or 
surgery.12 
The study included 60 participants, 20 were assigned to the treatment group and 40 to the 
placebo group. There were 32 women and 28 men participating in the study. There were 8 men and 20 
women in the treatment group and 20 of each gender in the control group. The average age for 
participants in the treatment group was 59.90 (+/-8.65) and 58.53 (+/-8.69) in the control group. The 
study lasted 3 months, the treatment group was given 1.5 grams of C. cassia capsules 3 times a day 
with meals and the control group took a placebo capsule three times a day. Pre and post trial HBA1C 
were obtained for all participants. Compliance was logged by capsule count and interviewing the 
participants. The baseline HBA1C in the treatment group was 8.14 (Mean SD=1.10) and 8.06 (Mean 
SD =1.05) in the control group. The post trial HBA1C in the treatment group was 7.76 (Mean 
SD=0∑95) and 7.87 (mean SD=0∑96) in the control group. The p value was 0.08, which was 
calculated using analysis of covariance- baseline value as covariate for the change from the baseline 
HBA1C. The decrease in the HBA1C of the treatment group was larger than that of the control group, 
but it did not have a statistically significant effect. 12 
DISCUSSION 
 This literature review was conducted to assess the efficacy of cinnamon supplementation on 
lowering HBA1C levels. For the most part, this review illustrates that cinnamon supplementation does 
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not have a statistically significant effect on lowering HBA1C (Table 1 and Table 2). The results 
obtained through this review show that much more research needs to be conducted.  In order to add 
cinnamon supplementation to diabetic therapy, larger studies need to be conducted and need to be 
longer in duration than the 3 to 4 month studies examined here. Future research should focus on 
reducing the risk of bias, increase in the number of randomized control trials, and need to be better at 
clearly defining method of blinding to have stronger validity and to eliminate the likelihood of bias. 
These studies also need to conduct and document post trial follow up care in order to assess any 
potential long term effects of cinnamon supplementation. Therefore, monitoring routine labs and vital 
signs is necessary throughout and after the trial period. Participants should be monitored closely for 
medication additions or changes in dosage in their current therapies during trials, to reduce the 
likelihood of these changes affecting the HBA1C and masking the true results of cinnamon 
supplementation therapy. Obtaining information on comorbid conditions or genetic disorders of insulin 
activity that may play a factor in the participant’s DM II will also advance research. Additional 
research should analyze if there is a relationship between the different types and forms of cinnamon 
supplementations and lowering HBA1C levels. Another factor to consider is if certain races have 
differing results with cinnamon supplementation. Also, it would be beneficial to focus on insulin 
sensitivity levels and glucose tolerance prior to enrolling participants in these trials, thus assessing the 
degree of control in DM II. Furthermore, information about diet, activity level, and lifestyle of the 
participants may provide better data when assessing the treatment effect. Another thing to consider is 
whether or not participants in the control group were aware that the placebo was not cinnamon, simply 
due to the smell. Finally, one can realize that further research is needed, and better studies need to be 
conducted in the future to deduce whether cinnamon supplementation has a significant effect on 
lowering HBA1C levels. Adding cinnamon to the diabetic regimen at this point in research seems 
futile.  The four studies that were included in this review will individually be analyzed hereafter.  
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 The study led by Crawford9 was the first to be reviewed. This study had some definite strengths 
and weaknesses. One of the strengths of this study was that it was the largest analyzed in this review. 
However, the actual number of participants completing the study was much lower than the number 
they used-since they used the results of the intention to treat analysis. The study selected participants 
from a patient database at the Eglin Air Force Base in Florida.9 This means that those that were 
selected had a documented history of disease and that it was fairly easy to recognize that they met the 
inclusion criteria for the study. This is far better than relying on patient self-reporting. All participants 
attended an information session about the study and also signed an informed consent form. The 
participants were to complete an 11 question survey regarding their prescription drug therapy, insulin 
use, and prior cinnamon intake (type, form, dose, supplement, and/or through diet). 9The results to the 
questionnaire were compared to the participant’s medical record for accuracy. This questionnaire is 
helpful in confirming the inclusion criteria of the participants. One downside to this trial was that those 
that were taking cinnamon prior to the trial were not excluded, but were rather encouraged to continue 
their pretrial cinnamon regimen. To see the true effect, participants that had never tried cinnamon 
supplementation and those not taking cinnamon regularly in their diet should have been the only ones 
to have been included in the trial. Furthermore, participants were randomized using a method called 
blocking. This method put the names of the participants in groups of 10 on a piece of paper, half were 
designated as treatment group and the other half as control group. The lists were created by a person 
not involved in the trial and so it was less likely to cause bias in the assignment of participants to the 
treatment versus control group.9 However, within the blocks of 10, the study does not specify if the 
participants allocated to the treatment and control group were similar in inclusion criteria. Allocation 
to each of the groups was revealed after drawing the participant names from a box. Neither the 
investigators nor the participants were blinded to the group assignment and this poses risk for bias. 
However, the lab personnel were blinded to group assignment of the patients and in a sense is a 
method of blinding. Another downside to the study, was that patients were allowed to change their 
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medications and adjust doses during the trial and this makes it hard to assess if the change in 
medication and/or dose adjustment or cinnamon supplementation is responsible for the effect on the 
HBA1C. Although, there were few participants who had such changes to their medications so it might 
not have influenced the results significantly.  It would still have been beneficial to disqualify those 
participants from the study, in order to assess cinnamon’s true effect on HBA1C. Furthermore, since 
the participants knew their group assignment and those in the control group had no intervention, it is 
difficult to detect if the act of taking the supplement had an effect on HBA1C or if the actual cinnamon 
supplement affected the HBA1C. This would have been a stronger study if the participants had been 
blinded to the group assignment and if both groups had been given some form of intervention. 
Compliance was measured by a phone call within the last 10 days of the study9, but it would have been 
better to monitor compliance throughout the trial by capsule count and/or capsule intake diary. 
Monitoring dietary intake and activity level would have been helpful as well. The study also did not 
mention that patients had any sort of follow up care after the trial was complete. They did mention that 
HBA1C was obtained days 90 to 95 after the trial, but is not clear to the reader if it was to obtain the 
post trial HBA1C or if it was for follow up; and if HBA1C was obtained daily on days 90 thru 95 to 
see any residual effect on HBA1C level. However, in this review it was assumed that post trial HBA1C 
levels were obtained any time between days 90 to 95.9 
 The next study reviewed was conducted by Mang et al.10 This study mentioned that it was a 
randomized placebo-controlled trial, but it did not mention the method of blinding or randomization. 
Also, the daily doses in the treatment and control group differed, 3 times daily and once daily, 
respectively.10 It is possible that participants among the groups could have communicated with each 
other in regards to the difference in daily dosing and this could have affected the results of the study. 
Although compliance was accounted for by capsule count and logging daily intake in a diary, it is 
difficult to confirm if all missed doses and capsule counts were truly accounted for and the reported 
number had to have been accepted in good faith. Furthermore, this study included diet and exercise 
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controlled DM II and drug controlled DM II patients. It can be postulated that those with diet and 
exercise controlled DM II may have a larger treatment effect because they are probably more insulin 
sensitive then the drug controlled DM II participants. It would have been interesting to separate them 
into 2 treatment groups and then compare their HBA1C results after cinnamon supplementation. Also, 
the participants were on many different anti-diabetic medications and it would have been beneficial to 
subdivide the participants within the treatment group according to the drug they were taking to 
compare the results at the end of the trial. This would provide insight on whether certain drugs work 
synergistically with cinnamon to have a larger treatment effect. The next thing that was considered was 
the years since diagnosis with DM II. It would have been helpful to see what relationship, if any, 
between years of diagnosis and insulin sensitizing effect of cinnamon supplementation. Perhaps those 
with longstanding disease may have a greater treatment effect with cinnamon supplementation. To go 
even a step further would be to test insulin sensitivity prior to enrollment of participants into the study, 
and then subdividing them into groups according to their sensitivities to evaluate the efficacy of 
cinnamon supplementation on lowering HBA1C. Next, the study took BMI, weight, and waist 
circumference into account.10 Perhaps if participants were organized by their respective levels into 
different subgroups and then given cinnamon supplementation, it may reveal what target metabolic 
levels are optimal for this therapy.  Another variable that should have been evenly distributed was 
gender. Gender in the treatment group was 63.6% (n=21) male and 36.4% (n=12) female, and 71.9% 
(n=23) male and 28.1% (n=9) female in the control group.10 The results may be obscured since gender 
distribution does not seem close to equal in both groups. Sample size was quite small, and gender 
could also play a role in efficacy of cinnamon supplementation in lowering HBA1C, yet this still 
remains to be seen.10 
The third study that was reviewed was by Blevins et al.11 This study was better than the others 
at monitoring changes to diabetic therapy by starting, stopping, or adjusting medications during the 
trial period, and those that had medication changes were disqualified from the trial. The study 
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mentions that participants were randomized and that participants and investigators were blinded to 
group assignment, but does not describe the method of randomization or blinding. Without an 
explanation for blinding and randomization, there is a margin for bias. This study was good in that it 
kept intervention dose similar, as twice daily and for three months in each of the groups. Another 
strong aspect of the study was compliance and follow-up were assessed with capsule count and a 
follow up appointment at 1,2, and 3 months.11 Another helpful part about the study was that it 
monitored dietary intake. Dietary intake was monitored by a monthly, 3 day food journal.11 It would 
have been more helpful to have type of food, amount, and calorie count recorded daily, in order to get 
a better idea of what sort of diet the participants had and if that had any bearing on the efficacy of 
cinnamon supplementation in lowering the HBA1C.  However, compliance might be difficult in trying 
to obtaining this type of food journal. The groups differed in age by 5 years, it would have been a 
better study had the age between groups been similar. Also, 77% of the treatment group was on anti-
diabetic therapy, whereas 91% of the control group was on such therapy.11 Since the results between 
the groups were very similar, it is hard to detect what factor influenced the decline in HBA1C, the anti-
diabetic therapy in addition to cinnamon supplementation or if there was a larger effect in the control 
group because more people in that group were on anti-diabetic therapy. This study had only 42 
participants and even with the intention to treat analysis being done for 57 participants, a true treatment 
effect may not have been observed due to the small sample size.11 
The last of the studies evaluated was conducted by Suppapitiporn et al.12 This study stood apart 
from the rest of the studies reviewed, in that it excluded persons with endocrinopathies and genetic 
insulin defects and those with poorly controlled DM II due to concurrent illness, infection, or surgery. 
Another positive aspect of this trial that other trials that were reviewed did not attempt to do was that it 
monitored liver function, BUN, creatinine, blood pressure, and monitored for adverse effects.12This is 
a very important aspect, and routine labs and vitals should be monitored in all trials. These are also 
vital to obtain, in order to rule out other causes of higher HBA1C levels. A big area of concern was 
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that the study mentions no method of blinding; also it states that the trial was randomized, but does not 
mention a method of randomization. Another downside to this trial was inequality between groups in 
reference to group size and gender. The control group consisted of 40 people, and 20 were in the 
treatment group. There were 12 women and 8 men in the treatment group and 20 men and 20 women 
in the control group.12It would have been ideal to have gender in similar numbers amongst the groups 
in order to observe any differences in treatment effect between genders. Compliance was monitored by 
capsule count and interview, but this process was not described in detail. It would have been better to 
describe when capsule count and interview were conducted, and how often. Also, other measures to 
ensure compliance could have been taken.12 
CONCLUSION 
 Cinnamon is widely used in many foods and as a supplement to treat many ailments. People 
have used it for many years for this purpose, but there has never been strong research supporting its 
efficacy. Thus far, research in the efficacy of cinnamon supplementation on lowering HBA1C has not 
yielded statistically significant results and the data does not strongly support its use. In order to see the 
true effect, future studies need to be larger in size and of longer duration to see long term effects of 
cinnamon on HBA1C. Researchers need to analyze cinnamon’s efficacy in relation to age, race, 
gender, diet, controlled DM II versus uncontrolled DM II, insulin sensitivity, comorbid conditions and 
different diabetic medications. Also, it is important to see if there is a synergistic relationship between 
cinnamon and certain DM II medication. Another interesting topic would be to see if there were 
different types and formulations of cinnamon are better at lowering HBA1C than others, as well as 
exploring what doses produce optimal results. Until all these variables are evaluated, it seems that 
adding cinnamon to a diabetic regimen is futile. Although, it can be considered in those that have tried 
diet, exercise, and multiple anti-diabetic medications, and still have difficulty attaining their goal 
HBA1C level. Cinnamon is inexpensive, potentially free of adverse effects, and is readily available. In 
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the future evidence may support its use in the diabetic regimen, but until then, it cannot the standard of 
care for patients with DM II.   
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Table 1   Summary of Selected Review Articles  
 
 
 
 
 
Study Year 
Published 
Patients/Population Intervention Comparison Outcome Study Type Validity 
(JADAD 
Score) 
Comments 
Crawford 2009 Any age, male/female, non insulin or 
insulin dependent, DM II patient with a 
HBA1C ≥7 within past 6 mos, not 
pregnant before the age of 18, and not 
allergic to cinnamon 
1gram daily of 
cinnamon x 3 
months 
No cinnamon 
supplementatio
n and no 
placebo 
Over a 90 day period 
of 1g cinnamon 
supplementation, 
HBA1C dropped by 
0.83% in the tx group, 
as compared to 0.37% 
in the control group 
Randomized 
control trial 
3/5 The investigators nor the patients were 
blinded, but the actual outcome assessor- 
the laboratory personnel were unaware of 
which group each of the results belonged 
to. Therefore, one could argue that it is 
somewhat of a single blind study 
 Mang et al 2006 Any age, male/female, non- insulin 
dependent, included those that take oral 
anti-hyperglycemic meds or even those 
controlled by their diet alone,  type 2 
diabetes 
112mg of aqueous  
Cinnamon extract 
(= to 1 gram of 
cinnamon) were 
given to the tx 
group daily x 
4months 
No cinnamon 
supplementatio
n 
(Cinnamomum 
Cassia)- i.e.- 
placebo group 
received 
identical pill 
containing 
crystalline 
cellulose TID  x 
4 months 
No significant changes 
were noted between 
pre and post trial 
HBA1C 
Randomized 
placebo-
controlled, 
double blind 
trial 
3/5 This study does state the participants were 
randomly assigned, but does not describe 
the method of randomization. It also 
describes itself as a double blind but does 
not describe how it met criteria for a double 
blind trial. 
Blevins et al 2007 Any age, male/female, non-insulin 
dependent type II diabetics with a HBA1C 
>6.0, that were not acutely ill, and those 
with no prior use of cinnamon 
supplementation 
500mg cinnamon 
cassia BID x 3 
months 
No cinnamon 
supplementatio
n, but received 
a placebo of 
wheat flour 
capsules, bid x 
30 days 
No significant changes 
were noted between 
the pre and post trial 
HBA1C 
Randomized 
placebo-
controlled 
double blind 
trial 
3/5 This study states the subjects were 
randomized, but the method used for 
randomization was not described. It says 
the investigators and subjects were blinded 
to group assignment & capsule content but 
does not describe how. 
Suppapitiporn 
et al 
2006 Ages 30-70, male/female, non-insulin 
dependent type II diabetics with HBA1C 
>7.0 within 1 month prior to study, those 
of child-bearing age had to be on 
contraception,  those without diabetes 
linked to genetic defects of insulin, 
pancreatitis, hemochromatosis, 
endocrinopathies, poorly controlled DM II 
due to concurrent illness, infection, or 
surgery, or those with liver or renal 
disease 
1.5 g cinnamon 
cassia powder 
capsule TID x 3 
months 
Placebo pill 
TID x  3 
months 
No significant changes 
were noted between 
pre and post trial 
HBA1C  
Randomized 
placebo 
control trial  
1/5 This study states that randomization was 
used, but does not describe method of 
randomization. It does not mention any 
form of blinding.  
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Table 2 Baseline and Post Trial HBA1C Comparison of the Reviewed Studies * 
       * Data are means +/- Standard deviation  
 
 
Author, Date Number of 
Participants 
in treatment 
group 
Treatment, 
dosage, and 
formulation 
Baseline 
HBA1C 
Treatment 
group 
Post trial 
HBA1C 
Treatment 
group 
Number of 
Participan
ts in 
control 
group 
Placebo 
yes/no 
dosage and 
form 
Baseline 
HBA1C 
Control 
group 
Post trial 
HBA1C 
Control 
group 
Crawford, 200912 55 C. cassia 500mg 
capsules, 2 daily 
with food 
8.47 +/- 1.8 7.64 +/- 1.7 54 No, usual 
care only 
8.28 +/- 1.3 7.91 +/- 1.5 
Mang et al, 2006 33 C. cassia extract 
capsule 112mg, 
(1g cinnamon) 3 
times daily with 
food  
6.86 +/- 
1.00 
6.71 +/- 0.73 32 Yes, 1 
capsule 
microcrystal
line 
cellulose 2 
times daily 
with food 
6.83 +/- 0.83 6.68 +/- 0.70 
Blevins et al, 2007 29 C. cassia 500mg 
capsules, 2 times 
daily with food 
7.2 +/- 0.3 7.0 +/- 0.1 28 Yes, 1 
capsule 
wheat flour 
2 times daily 
with food 
7.1 +/-  0.2 7.0 +/- 0.2 
Suppapitiporn et al, 
2006 
20 Cinnamon powder 
capsule 1.5 g 3 
times daily with 
food 
8.14  +/- 
1.10 
7.76 (0∑95) 40 Yes, 1 
placebo 
capsule 3 
times daily 
with food 
8.06 +/- 1.05 7.87 (0∑96) 
